We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $532M
1-Year Est. Return 171.17%
This Fund
S&P 500
This Quarter Est. Return
+19.45%
1 Year Est. Return
+171.17%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$532M
AUM Growth
+$53.4M
Cap. Flow
-$19.6M
Cap. Flow %
-3.69%
Top 10 Hldgs %
56.72%
Holding
51
New
10
Increased
15
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
AVLN
Avalyn Pharma
AVLN
+$48.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
PBLS
Parabilis Medicines Inc
PBLS
+$22.8M
4
GILD icon
Gilead Sciences
GILD
+$13.9M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$11.2M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$46.1M
2
ASND icon
Ascendis Pharma A/S
ASND
+$22.7M
3
TERN
Terns Pharmaceuticals
TERN
+$21.6M
4
SLNO
Soleno Therapeutics
SLNO
+$19.3M
5
BSX icon
Boston Scientific
BSX
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVLN
1
Avalyn Pharma
AVLN
$1.66B
$55.2M 10.37%
+1,675,830
New +$48.4M
JNJ icon
2
Johnson & Johnson
JNJ
$663B
$35.3M 6.63%
+138,946
New +$32.4M
GILD icon
3
Gilead Sciences
GILD
$187B
$34M 6.39%
269,309
+105,404
+64% +$13.9M
BBIO icon
4
BridgeBio Pharma
BBIO
$14.6B
$33.9M 6.37%
455,041
+23,027
+5% +$1.61M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.84B
$26.6M 4.99%
1,215,698
+172,028
+16% +$3.58M
DFTX
6
Definium Therapeutics
DFTX
$5.12B
$26.5M 4.97%
562,672
-475,312
-46% -$11.7M
BMY icon
7
Bristol-Myers Squibb
BMY
$136B
$23.8M 4.47%
412,961
-7,766
-2% -$446K
PBLS
8
Parabilis Medicines Inc
PBLS
$4.99B
$22.6M 4.24%
+824,043
New +$22.8M
NTRA icon
9
Natera
NTRA
$47.3B
$22.3M 4.19%
82,181
+11,274
+16% +$2.4M
INCY icon
10
Incyte
INCY
$25.7B
$21.7M 4.08%
191,627
+9,526
+5% +$945K
SEPN
11
Septerna Inc
SEPN
$1.72B
$18M 3.37%
536,152
+241,792
+82% +$6.86M
MLYS icon
12
Mineralys Therapeutics
MLYS
$2.49B
$17.5M 3.29%
648,722
+209,681
+48% +$5.75M
HTFL
13
Heartflow Inc
HTFL
$4.25B
$17.1M 3.22%
583,055
+179,467
+44% +$5.39M
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$1.21B
$16.1M 3.03%
1,080,888
+188,955
+21% +$2.62M
GPCR icon
15
Structure Therapeutics
GPCR
$3.38B
$14.8M 2.79%
276,550
+21,171
+8% +$937K
PTGX icon
16
Protagonist Therapeutics
PTGX
$9.43B
$13.1M 2.46%
+106,799
New +$11.2M
IRON icon
17
Disc Medicine
IRON
$3.04B
$11.7M 2.19%
159,384
+36,406
+30% +$2.5M
EW icon
18
Edwards Lifesciences
EW
$51.8B
$11.3M 2.12%
124,778
-19,829
-14% -$1.66M
AXSM icon
19
Axsome Therapeutics
AXSM
$10.8B
$10.6M 1.99%
+43,182
New +$9.36M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$1.51B
$10.6M 1.98%
316,252
-534,545
-63% -$13.3M
KLRA
21
Kailera Therapeutics
KLRA
$2.1B
$10.3M 1.94%
+468,750
New +$10.3M
KPTI icon
22
Karyopharm Therapeutics
KPTI
$40.6M
$9.19M 1.73%
940,855
+43,146
+5% +$374K
ODTX
23
Odyssey Therapeutics
ODTX
$1.38B
$8.57M 1.61%
+457,839
New +$8.03M
ASND icon
24
Ascendis Pharma A/S
ASND
$17.7B
$8.47M 1.59%
31,759
-97,352
-75% -$22.7M
KARD
25
Kardigan Inc
KARD
$1.95B
$7.45M 1.4%
+312,500
New +$7.23M
1
2 3

Similar funds

3IP
3Chopt Investment Partners Richmond, Virginia $532M AUM 35.46% 1-Year Est. Return
ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
IA
Icon Advisers Greenwood Village, Colorado $532M AUM 56.47% 1-Year Est. Return
KM
KP Management Edina, Minnesota $532M AUM 118.04% 1-Year Est. Return
SIA
Sovereign Investment Advisors Phoenix, Arizona $533M AUM 16.78% 1-Year Est. Return
TCMX
Technology Crossover Management XI Menlo Park, California $533M AUM 42.1% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
NAMP
NorthStar Asset Management (Pennsylvania) Blue Bell, Pennsylvania $531M AUM 27.28% 1-Year Est. Return

Catalio Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Catalio Capital Management held 51 positions worth $532M, up 11% from $479M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Catalio Capital Management withdrew a net $19.6M in Q2 2026, closing 12 positions and reducing 9 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $21.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Catalio Capital Management opened a new position in Avalyn Pharma worth $55.2M.

  • Catalio Capital Management's largest Q2 2026 buy was Avalyn Pharma: 1,675,830 shares worth $55.2M.
  • Catalio Capital Management added most to Gilead Sciences in Q2 2026, an estimated $13.9M increase.
  • Catalio Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $46.1M.
  • Catalio Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $21.6M.
  • Catalio Capital Management's ten largest holdings make up 57% of its $532M portfolio in Q2 2026.
  • Catalio Capital Management opened 10 new positions and closed 12 in Q2 2026.
  • Catalio Capital Management's portfolio value rose 11% quarter-over-quarter to $532M.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.